National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder
MediciNova, Inc. (MNOV)
Last medicinova, inc. earnings: 4/23 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
medicinova.com/investor-relations/media-archive
Company Research
Source: GlobeNewswire
LA JOLLA, Calif., Aug. 20, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institute on Alcohol Abuse and Alcoholism (NIAAA), which is part of the National Institutes of Health (NIH), will fund a Phase 2b clinical trial to evaluate MN-166 (ibudilast) as a potential treatment to decrease alcohol consumption in treatment-seeking patients with alcohol use disorder (AUD). This study is a randomized, double-blind, placebo-controlled outpatient trial which will enroll up to 132 patients. The NIAAA R01 research funding was awarded to Principal Investigator Dr. Lara Ray, PhD, ABPP, at the University of California, Los Angeles' (UCLA) Departments of Psychology, and Psychiatry and Biobehavioral Sciences Brain Research Institute, based on her recent findings that MN-166 (ibudilast) was associated with mood improvements
Show less
Read more
Impact Snapshot
Event Time:
MNOV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNOV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNOV alerts
High impacting MediciNova, Inc. news events
Weekly update
A roundup of the hottest topics
MNOV
News
- MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanGlobeNewswire
- MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis SocietyGlobeNewswire
- Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology [Yahoo! Finance]Yahoo! Finance
MNOV
Earnings
- 11/9/23 - Beat
MNOV
Sec Filings
- 2/15/24 - Form 10-K
- 1/19/24 - Form S-8
- 1/19/24 - Form S-8
- MNOV's page on the SEC website